Navitoclax improves acute-on-chronic liver failure by eliminating senescent cells in mice.

Yusuke WatanabeHiroyuki AbeNaruhiro KimuraYoshihisa AraoNatsuki IshikawaMaeda YuichiroToru SetsuAkira SakamakiHiroteru KamimuraTakeshi YokooKenya KamimuraAtsunori TsuchiyaShuji Terai

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2023)

Navi may ameliorate ACLF damage by eliminating senescent cells in the liver, downregulating senescence-associated secretory phenotype factors, and upregulating mitochondrial functions. We believe that this novel approach using Navi will pave the way for ACLF treatment.

Keyphrases

liver failure
induced apoptosis
cell cycle arrest
oxidative stress
hepatitis b virus
endoplasmic reticulum stress
type diabetes
dna damage
cell death
drug induced
endothelial cells
signaling pathway
intensive care unit
cell proliferation
acute respiratory distress syndrome
respiratory failure
replacement therapy